Loading…
Reinsurance Group of America, Incorporated
NYSE: RGA Financials Insurance 🔎 Screen
🏹 Trader: 🚀 Stage 2 + Near High 📈 Stage 2 🎯 Near 52W High | BRS 80 Ready View all →
📈 Stage 2 detected Find the fundamental catalyst → → run Growth Triggers in Ask AI
$16.3B
Market Cap
11.5
P/E
1.11
PEG
8.3%
ROCE
9.7%
ROE
0.43
D/E
8.0%
OPM
-2.8%
% from 52W High
79
α RS
🔍 RGA is showing a high-conviction setup because it matches 4 of 39 tracked screener presets, RS Rating is 79, and an ECS of 69.3 last quarter. Net: Broad signal stack, not a recommendation. ? Conviction RS Rating ECS
Sources
Conviction 4/39 · RS Rating 79 · ECS 69.3
⚖️ Compare 🔒 Generate Report 🔒 Research Packet 📚 Guides
🌏 Global Investor Returns
Currency-adjusted total returns for RGA including FX impact
🌏
Click 🌏 Returns tab to load data
📈 Price History
Ratio Health
Excellent
Good
Average
Poor
By Category
📊 Sector Averages
About

Reinsurance Group of America, Incorporated provides life and health, and asset-intensive reinsurance in the United States, Latin America, Canada, Europe, the Middle East, Africa, Asia, and Australia. It offers individual and group life and health, disability, long-term care, and critical illness reinsurance; and financial solutions, such as asset-intensive reinsurance, longevity reinsurance, stable value products, pension risk transfer transactions, and capital solutions. The company also provides reinsurance for mortality, morbidity, lapse, and investment-related risks; coinsurance of payout annuities; underwritten annuities; funding agreement backed note program and other capital motivated solutions; and superannuation. Reinsurance Group of America, Incorporated was founded in 1973 and is headquartered in Chesterfield, Missouri.

Key Ratios Snapshot
📈 Growth Pattern
📊 Quick Scorecard
Loading…
⭐ Superinvestors Holding RGA
View All Superinvestors →
Manager Shares Value % of Fund Period
Steve Cohen Point72 Asset Management 333.5K $68.1M 0.09% Mar 2026
Jim Simons Renaissance Technologies LLC 27.6K $5.6M 0.01% Mar 2026

SEC Form 13F data. 45-day lag from quarter end.

🔒
Premium Feature
AI-generated 10-section company profile — business model, financials, strengths, risks & management quality
Upgrade to Premium
Already a member? Log in
📐
3-Statement Financial Model
Bear / Base / Bull projections · DCF fair value · Reverse-DCF
Open Model →
🎙 Management Tone Confident Specific ↑ Improving 4 quarters Full tone analysis in Intelligence →
📊 MIXED RGA Q1 2026 adjusted operating income $611M, EPS $6.97, excess capital $2.4B
Revenue & Profitability
Pre-tax adjusted operating income was $611 million ($6.97 per share after tax). Trailing 12-month adjusted operating ROE was 16.2%. Premium growth was 5% overall, with U.S. Traditional up about 1%. Capital deployed into in-force transactions was $338 million. Excess capital was $2.4 billion. Share repurchases totaled $50 million in the quarter.
Outlook
Management expressed high confidence for 2026 and beyond, citing strong fundamentals, a healthy pipeline, and favorable economic claims experience. The company expects to achieve intermediate-term financial targets through disciplined execution and capital deployment. No major macro headwinds were highlighted.
Growth Drivers
Key growth drivers include strong momentum in Asia Pacific (Japan, Korea), U.S. individual life strategic underwriting initiatives (record volumes), and continued leadership in U.K. longevity. The Equitable transaction adds to Financial Solutions results. In-force and flow pipelines are diversified globally.
Balance Sheet & CapEx
Not discussed in this earnings call.
Margins
Not discussed in this earnings call.
Key Risks
Risks include seasonal claims volatility (Q1 winter claims), variable investment income below the 7% assumed return, regulatory changes such as AG 55 in the U.S. and U.K. captive reinsurance proposals. Management views these as manageable given strong capital and diversification. Credit impairments remain favorable.
Generated by AI · Q1 2026 results · Not investment advice
🔒
Free Account Required

Create a free Finmagine account to access Finmagine™ Scorecard.

See how this company scores across 5 dimensions — Financial Health, Growth Prospects, Competitive Position, Management Quality, and Valuation — powered by 30+ computed ratios.

Create Free AccountLog In
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Ask AI.

Get 25 expert AI analysis templates — Business KPIs, Comprehensive, Forensic Governance, Peer Comparison, Risk-Reward, Full Research Report, IPO Decoder, Red Flag Detector, and more — ready to paste into ChatGPT, Claude, Gemini, or Perplexity.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Peer Comparison.

Compare this company side-by-side against its sector peers with financial metrics, ratio benchmarking, and relative performance across all key dimensions.

Upgrade to PremiumCreate Free Account
✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter
🔍
🔎 See cross-company document search → ?
📞 Earnings Call Transcripts (5)
Q2 2026 Q2 2026 2026-08-07
Record quarterly results driven by strong investment returns, favorable claims, and disciplined capital deployment across all regions. Adjusted operating income reached $761 million, with robust new business momentum and a strong capital position supporting confidence in meeting intermediate-term financial targets.
Q1 2026 Q1 2026 2026-05-08
Strong Q1 performance driven by broad-based growth, favorable claims, and disciplined capital deployment. Robust capital position supports continued shareholder returns and confidence in meeting financial targets for 2026 and beyond.
Q4 2025 Q4 2025 2026-02-06
Record Q4 and full-year results featured strong EPS, ROE, and in-force value growth, with robust capital deployment and a positive outlook for 2026. Segment performance was strong across all regions, and the exit from U.S. group healthcare is expected to improve future results.
Q3 2025 Q3 2025 2025-10-31
Record operating EPS and strong premium growth were driven by robust performance in Asia, EMEA, and U.S. Financial Solutions, with the Equitable transaction and strategic capital deployment fueling future earnings. Capital position remains strong, supporting continued shareholder returns.
Q2 2025 Q2 2025 2025-08-01
Q2 2025 operating EPS was $4.72, with adjusted ROE at 14.3%. Results were impacted by large claims in U.S. individual life and healthcare excess, but capital and business momentum remain strong. The Equitable transaction closed, and premium growth was robust across regions.
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Catalyst Timeline.

Every result, order win, insider trade, ECS update, earnings-call, and SEC announcement for this company — in one chronological lane.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Full Report.

Read the complete Finmagine™ investment research report — comprehensive fundamental analysis, business model assessment, competitive positioning, and investment recommendation.

Upgrade to PremiumCreate Free Account

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯
Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.
📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

Financial Model
Projections are built from each company's audited annual financials (Income Statement, Balance Sheet, Cash Flow) over the last 5 fiscal years. Forward assumptions — revenue growth %, EBITDA margin, D&A (USD millions), interest expense, tax rate, and capex — are AI-generated using historical context and refreshed twice a year: after the December results season and after the September/Q4 results season.

DCF Valuation
Fair Value = Σ(FCFt / (1+WACC)t) + Terminal Value. Terminal Value uses the Gordon Growth Model: FCF5 × (1+g) / (WACC−g). Default WACC: 10% (US risk-free ~4.5%, equity risk premium ~5.5%). Default terminal growth: 3% (long-run US nominal GDP proxy).

CAGR Tracker
Expected 5-year CAGR = (DCF Fair Value / Current Price)1/5 − 1. Assumes fair value is reached in exactly 5 years — a mechanical estimate only.

Data Sources & Limitations
Financial statements sourced from public filings. Prices updated daily. Forward assumptions are AI-generated. All monetary values in USD millions. Non-US ADR companies may have currency conversion inaccuracies. Models are point-in-time and do not update intra-quarter or account for M&A, macro shocks, or extraordinary items.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.